Exploring the Breakthrough of VK2735 in Metabolic Disorders: Insights from Viking Therapeutics' Phase 1 Study (oral formulation)

Executed on:May 7, 2024 1:00 PM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: Harvard Medical SchoolMedical Director, Obesity Clinic Program and Inpatient Diabetes Program & Associate Professor at Harvard Medical School.
Manages ~1,000 patients with diabetes and obesity
Research interests include diabetes and obesity, metabolic syndrome and obesity and cardiovascular disease with a focus on understanding metabolic and cardiovascular benefits of lifestyle changes and weight loss. 

Interview Goal

This interview aims to explore the pivotal findings of Viking Therapeutics' recent Phase 1 study of VK2735, an oral tablet formulation of a dual GLP-1/GIP receptor agonist, focusing on its role in metabolic disorder treatment, particularly obesity. The goal is to gain deeper insights into VK2735's efficacy, safety profile, and its prospective impact on the management of metabolic disorders.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.